Technology
CBIZ REPORTS SECOND-QUARTER AND FIRST-HALF 2024 RESULTS AND ANNOUNCES AGREEMENT TO ACQUIRE MARCUM
Published
2 years agoon
By
SECOND-QUARTER HIGHLIGHTS:
TOTAL REVENUE UP 5.4%; SAME-UNIT REVENUE UP 2.8%GAAP EPS DOWN 26.4%; ADJUSTED EPS DOWN 9.1%; INCLUDES MARCUM ACQUISITION-RELATED EXPENSE OF $6.7MNET INCOME DOWN 26.3%; ADJUSTED EBITDA DOWN 6.9%
SIX-MONTH HIGHLIGHTS:
TOTAL REVENUE UP 7.2%; SAME-UNIT REVENUE UP 4.4%GAAP EPS DOWN 3.0%; ADJUSTED EPS UP 1.5%; INCLUDES MARCUM ACQUISITION-RELATED EXPENSE OF $6.7MNET INCOME DOWN 3.3%; ADJUSTED EBITDA UP 1.0%
CLEVELAND, July 31, 2024 /PRNewswire/ — CBIZ, Inc., (NYSE: CBZ) (“CBIZ” or the “Company”), a leading provider of financial, insurance and advisory services, today announced results for the second quarter and six months ended June 30, 2024.
In a separate press release issued today, CBIZ also announced it has entered into a definitive agreement to acquire Marcum LLP (“Marcum”), a national accounting and advisory firm. Upon closing, CBIZ will become the seventh-largest accounting services provider in the U.S. The cash-and-stock transaction valued at approximately $2.3 billion is expected to close in the fourth quarter. CBIZ incurred approximately $6.7 million in fees related to the Marcum transaction and results for the second quarter are impacted by $0.10 per share. The press release announcing this transaction is available on CBIZ’s website at https://cbiz.gcs-web.com/investor-overview.
Second-Quarter and First-Half 2024 Results
During the 2024 second quarter, CBIZ experienced the departure of a small group of producers and support staff within our Property and Casualty business and a loss of clients served by this group. Included in reported results is the impact of $0.03 in Adjusted earnings per share for the 2024 second quarter and first half. The impact to full-year 2024 Adjusted earnings per share is expected to be approximately $0.06.
For the 2024 second quarter, CBIZ recorded revenue of $420.0 million, an increase of $21.5 million, or 5.4%, compared with $398.5 million reported for the same period in 2023. Acquired operations contributed $10.5 million, or 2.6%, to second-quarter 2024 revenue growth. Same-unit revenue increased by $11.0 million, or 2.8%, for the quarter, compared with the same period a year ago. Net income was $19.8 million, or $0.39 per diluted share, for the quarter, compared with $26.9 million, or $0.53 per diluted share, for the same period a year ago.
For the six months ended June 30, 2024, CBIZ recorded revenue of $914.3 million, an increase of $61.2 million, or 7.2%, over the $853.1 million recorded for the same period in 2023. Acquired operations contributed $23.3 million, or 2.7%, to revenue growth in the six months ended June 30, 2024. Same-unit revenue increased by $37.9 million, or 4.4%, for the six months ended June 30, 2024, compared with the same period a year ago. Net income was $96.7 million, or $1.92 per diluted share, for the six months ended June 30, 2024, compared with $100.0 million, or $1.98 per diluted share, for the same period a year ago.
Excluding nonrecurring acquisition-related integration expenses and professional fees incurred related to the Marcum transaction, Adjusted net income was $25.0 million in the second quarter of 2024, compared with Adjusted net income of $27.6 million for the same period a year ago. Adjusted earnings per share was $0.50 for the second quarter of 2024, a decrease of 9.1%, compared with Adjusted earnings per share of $0.55 for the same period a year ago. Adjusted EBITDA for the second quarter of 2024 was $50.7 million, down 6.9%, compared with $54.4 million for the same period in 2023.
For the six months ended June 30, 2024, Adjusted net income was $102.5 million, compared with Adjusted net income of $102.0 million for the same period a year ago. Adjusted earnings per share was $2.04 for the six months ended June 30, 2024, an increase of 1.5%, compared with Adjusted earnings per share of $2.01 for the same period a year ago. Adjusted EBITDA for the six months ended June 30, 2024, was $169.5 million, compared with $167.8 million for the same period in 2023.
Schedules reconciling Adjusted net income, Adjusted earnings per share and Adjusted EBITDA to the most directly comparable GAAP measures can be found in the tables included at the end of this release.
The balance outstanding on the Company’s unsecured credit facility on June 30, 2024, was $381.0 million, with $209.8 million of unused borrowing capacity.
CEO Commentary
Jerry Grisko, CBIZ President and Chief Executive Officer, said, “We are pleased to report that our second-quarter results were generally in line with our expectations and that the overall health of our business remains strong. At the same time, we did experience a small number of unique headwinds that impacted our results for the quarter. Among these headwinds were the exit of a small group of producers from our Property and Casualty Insurance business and some evidence of clients delaying investment decisions and tightening discretionary spending. While our clients remain largely optimistic about the second half of the year, we find that any uncertainty in the market is amplified in an election year given concerns around regulations and interest rates. The nature of our resilient business model, with a high rate of recurring revenue and variable expense, enables us to maintain our performance even in less predictable business conditions.”
Grisko continued, “This morning we announced our agreement to acquire Marcum. After closing, the new, combined business will solidify our position as a leading provider of professional services to middle market businesses and is projected to be accretive to Adjusted Earnings in its first full year of operations. On a combined basis, we will become the seventh-largest accounting services provider in the country with revenues of approximately $2.8 billion, will employ over 10,000 team members and will serve more than 135,000 clients with a unique breadth of services and depth of expertise, including Benefits & Insurance services. We are excited about our future together and the opportunities this will provide to our people, the solutions we will bring to our clients, and the value we expect to create for our shareholders.”
2024 Outlook
With an expected close in fourth quarter of 2024, our current guidance excludes the impact of the Marcum acquisition. Based on expectations for the remainder of 2024, and due to the projected $0.06 per share full year impact of the loss of Property and Casualty business, the Company expects the following:
Total revenue to grow within a range of 7% to 9% over the prior year.Effective tax rate of approximately 28%.Weighted average fully diluted share count of approximately 50.0 to 50.5 million shares.GAAP fully diluted earnings per share to grow within a range of 6% to 8%, to $2.53 to $2.58 per share, compared with the $2.39 per share reported for 2023.Adjusted fully diluted earnings per share to grow within a range of 10% to 12%, to $2.64 to $2.69 per share, compared with the $2.41 per share reported for 2023.
Conference Call
CBIZ will host a conference call at 11 a.m. (ET) today to discuss its second-quarter and first-half financial results as well as the Marcum acquisition announcement. The call will be webcast and an archived replay will be available at https://cbiz.gcs-web.com/investor-overview. Participants can register at https://dpregister.com/sreg/10191052/fd1f3d903c.
About CBIZ
CBIZ is a leading provider of financial, insurance and advisory services to businesses throughout the United States. Financial services include accounting, tax, government health care consulting, transaction advisory, risk advisory, and valuation services. Insurance services include employee benefits consulting, retirement plan consulting, property and casualty insurance, payroll, and human capital consulting. With more than 120 offices in 33 states, CBIZ is one of the largest accounting and insurance brokerage providers in the U.S. For more information, visit www.cbiz.com.
Forward-Looking Statements
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to: we may be more sensitive to revenue fluctuations than other companies, which could result in fluctuations in the market price of our common stock; payments on accounts receivable may be slower than expected, or amounts due on receivables or notes may not be fully collectible; we are dependent on the services of our executive officers, other key employees, producers and service personnel, the loss of whom may have a material adverse effect on our business, financial condition and results of operations; restrictions imposed by independence requirements and conflict of interest rules may limit our ability to provide services to clients of the attest firms with which we have contractual relationships and the ability of such attest firms to provide attestation services to our clients; our goodwill and intangible assets could become impaired, which could lead to material non-cash charges against earnings; certain liabilities resulting from acquisitions are estimated and could lead to a material non-cash impact on earnings; governmental regulations and interpretations are subject to changes, which could have a material adverse effect on our clients, our business, our business services operations, our business models, or our revenue; changes in the United States healthcare or public health environment, including new healthcare legislation or regulations, may adversely affect the revenue and margins in our or our clients’ businesses; we are subject to risks relating to processing customer transactions for our payroll and other transaction processing businesses; cyber-attacks or other security breaches involving our computer systems or the systems of one or more of our vendors or clients could materially and adversely affect our business; we are subject to risk as it relates to software that we license from third parties; we could be held liable for errors and omissions, contract claims, or other litigation judgments or expenses; the future issuance of additional shares could adversely affect the price of our common stock; our principal stockholders may have substantial control over our operations; we require a significant amount of cash for interest payments on our debt and to expand our business as planned; terms of our credit facility may adversely affect our ability to run our business and/or reduce stockholder returns; our failure to satisfy covenants in our debt instruments could cause a default under those instruments; we are reliant on information processing systems and any failure of these systems could have a material adverse effect on our business, financial condition and results of operations; we may not be able to acquire and finance additional businesses which may limit our ability to pursue our business strategy; the business services industry is competitive and fragmented; if we are unable to compete effectively, our business, financial condition and results of operations may be negatively impacted; there is volatility in our stock price.
With respect to the agreement to acquire Marcum, such risks and uncertainties include, but are not limited to: the ability of the parties to consummate the transaction in a timely manner or at all; satisfaction of the conditions precedent to consummation of the transaction, including the ability to secure regulatory approvals in a timely manner or at all, and the approval by Marcum’s partners and the approval by the Company’s stockholders; the possibility of litigation related to the transaction and the effects thereof; the possibility that anticipated benefits and/or synergies of the transaction will not be achieved in a timely manner or at all; the possibility that the costs of the transaction and/or liabilities assumed will be more significant than anticipated; the possibility that integration will prove more costly and/or time consuming than anticipated; the possibility that the transaction could disrupt ongoing plans and operations of the parties or their respective relationships with clients, other business partners and employees; the possibility that the financing will not be obtained as anticipated and the effects of the increased leverage of the Company following the transaction; and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”).
Such forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Should one or more of these risks materialize, or should the underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. Consequently, no forward-looking statements can be guaranteed.
A more detailed description of such risks and uncertainties may be found in “Item 1A. Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s other filings with the SEC at www.sec.gov.
All forward-looking statements made in this release are made only as of the date hereof. The Company does not undertake any obligation to publicly update or correct any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
ADDITIONAL INFORMATION ABOUT THE TRANSACTION AND WHERE TO FIND IT
In connection with the transaction with Marcum, the Company will file a proxy statement with the SEC. The definitive proxy statement will be mailed to the Company’s stockholders and will contain important information about the transaction and related matters. THE COMPANY’S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT CAREFULLY WHEN IT BECOMES AVAILABLE BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE TRANSACTION BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION. The definitive proxy statement and other relevant materials (when they become available) and any other documents filed by the Company with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, stockholders will be able to obtain free copies of the definitive proxy statement from the Company on the Investor Relations page of the Company’s website, www.cbiz.com, or by writing to us at Attention: Investor Relations Department, 5959 Rockside Woods Blvd. N., Suite 600, Independence, Ohio 44131.
PARTICIPANTS IN THE SOLICITATION
The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the transaction with Marcum. Information with respect to the Company’s directors and executive officers is set forth in the Company’s Proxy Statement on Schedule 14A for its 2024 Annual Meeting of Stockholders, which was filed with the SEC on March 25, 2024, and its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the SEC on February 23, 2024. These documents are available free of charge at the SEC’s website at www.sec.gov, or from the Company on the Investor Relations page of the Company’s website, www.cbiz.com, or by writing to us at Attention: Investor Relations Department, 5959 Rockside Woods Blvd. N., Suite 600, Independence, Ohio 44131. Additional information regarding the interests of participants in the solicitation of proxies in connection with the transaction will be included in the proxy statement that the Company intends to file with the SEC.
CBIZ, INC.
FINANCIAL HIGHLIGHTS (UNAUDITED)
THREE MONTHS ENDED JUNE 30, 2024 AND 2023
(In thousands, except percentages and per share data)
Three Months Ended June 30,
2024
%
2023
%
Revenue
$ 420,012
100.0 %
$ 398,502
100.0 %
Operating expenses (1)
366,368
87.2
343,987
86.3
Gross margin
53,644
12.8
54,515
13.7
Corporate general and administrative expenses (1)
22,050
5.2
15,793
4.0
Operating income
31,594
7.6
38,722
9.7
Other (expense) income:
Interest expense
(5,884)
(1.4)
(5,534)
(1.4)
Other income, net (1) (2)
2,483
0.6
5,421
1.4
Total other expense, net
(3,401)
(0.8)
(113)
—
Income before income tax expense
28,193
6.8
38,609
9.7
Income tax expense
8,400
11,746
Net income
$ 19,793
4.7 %
$ 26,863
6.7 %
Diluted earnings per share
$ 0.39
$ 0.53
Diluted weighted average common shares outstanding
50,276
50,385
Other data:
Adjusted EBITDA (3)
$ 50,683
$ 54,435
Adjusted EPS (3)
$ 0.50
$ 0.55
(1)
CBIZ sponsors a deferred compensation plan, under which a CBIZ employee’s compensation deferral is held in a rabbi trust and invested accordingly as directed by the employee. Income and expenses related to the deferred compensation plan are included in “Operating expenses” and “Corporate general and administrative expenses,” and are directly offset by deferred compensation gains or losses in “Other expense, net.” The deferred compensation plan has no impact on “Income before income tax expense.”
Income and expenses related to the deferred compensation plan for the three months ended June 30, 2024, and 2023, are as follows (in thousands):
Three Months Ended June 30,
2024
% of Revenue
2023
% of Revenue
Operating expense
$ 2,283
0.5 %
$ 5,102
1.3 %
Corporate general and administrative expense
323
0.1 %
631
0.2 %
Other income, net
2,606
0.6 %
5,733
1.4 %
Excluding the impact of the previously mentioned income and expenses related to the deferred compensation plan, the operating results for the three months ended June 30, 2024, and 2023, are as follows (in thousands):
Three Months Ended June 30,
2024
2023
As Reported
Deferred
Compensation
Plan
Adjusted
% of Revenue
As Reported
Deferred
Compensation
Plan
Adjusted
% of Revenue
Gross margin
$ 53,644
$ 2,283
$ 55,927
13.3 %
$ 54,515
$ 5,102
$ 59,617
15.0 %
Operating income
31,594
2,606
34,200
8.1 %
38,722
5,733
44,455
11.2 %
Other income (expense), net
2,483
(2,606)
(123)
— %
5,421
(5,733)
(312)
(0.1) %
Income before income tax expense
28,193
—
28,193
6.8 %
38,609
—
38,609
9.7 %
(2)
Included in “Other income (expense), net” for the three months ended June 30, 2024, and 2023, is expense of $0.2 million and $0.8 million, respectively, related to net changes in the fair value of contingent consideration related to CBIZ’s prior acquisitions.
(3)
Refer to the schedules reconciling Adjusted earnings per share and Adjusted EBITDA to the most directly comparable GAAP measures at the end of this release, and for additional information as to the usefulness of the Non-GAAP financial measures to shareholders and investors.
CBIZ, INC.
FINANCIAL HIGHLIGHTS (UNAUDITED)
SIX MONTHS ENDED JUNE 30, 2024 AND 2023
(In thousands, except percentages and per share data)
Six Months Ended June 30,
2024
%
2023
%
Revenue
$ 914,309
100.0 %
$ 853,108
100.0 %
Operating expenses (1)
742,853
81.2
684,998
80.3
Gross margin
171,456
18.8
168,110
19.7
Corporate general and administrative expenses (1)
40,761
4.5
31,391
3.7
Operating income
130,695
14.3
136,719
16.0
Other (expense) income:
Interest expense
(10,395)
(1.1)
(9,175)
(1.1)
Gain on sale of operations, net
—
—
99
—
Other income, net (1) (2)
11,907
1.3
10,533
1.2
Total other income, net
1,512
0.2
1,457
0.1
Income before income tax expense
132,207
14.5
138,176
16.1
Income tax expense
35,530
38,153
Net income
96,677
10.6 %
100,023
11.7 %
Diluted earnings per share
$ 1.92
$ 1.98
Diluted weighted average common shares outstanding
50,248
50,639
Other data:
Adjusted EBITDA (3)
$ 169,513
$ 167,783
Adjusted EPS (3)
$ 2.04
$2.01
(1)
CBIZ sponsors a deferred compensation plan, under which a CBIZ employee’s compensation deferral is held in a rabbi trust and invested accordingly as directed by the employee. Income and expenses related to the deferred compensation plan are included in “Operating expenses” and “Corporate general and administrative expenses,” and are directly offset by deferred compensation gains or losses in “Other income (expense), net.” The deferred compensation plan has no impact on “Income before income tax expense.”
Income and expenses related to the deferred compensation plan for the six months ended June 30, 2024, and 2023, are as follows (in thousands):
Six Months Ended June 30,
2024
% of Revenue
2023
% of Revenue
Operating expenses
$ 10,859
1.2 %
$ 9,862
1.2 %
Corporate general and administrative expenses
1,380
0.2 %
1,273
0.1 %
Other income (expense), net
12,239
1.3 %
11,135
1.3 %
Excluding the impact of the above-mentioned income and expenses related to the deferred compensation plan, the operating results for the six months ended June 30, 2024, and 2023, are as follows (in thousands):
Six Months Ended June 30,
2024
2023
As Reported
Deferred
Compensation
Plan
Adjusted
% of Revenue
As Reported
Deferred
Compensation
Plan
Adjusted
% of Revenue
Gross margin
$ 171,456
$ 10,859
$ 182,315
19.9 %
$ 168,110
$ 9,862
$ 177,972
20.9 %
Operating income
130,695
12,239
142,934
15.6 %
136,719
11,135
147,854
17.3 %
Other income (expense), net
11,907
(12,239)
(332)
— %
10,533
(11,135)
(602)
(0.1) %
Income before income tax expense
132,207
—
132,207
14.5 %
138,176
—
138,176
16.1 %
(2)
Included in “Other income (expense), net” for the six months ended June 30, 2024, and 2023, is expense of $0.6 million and $1.4 million, respectively, related to net changes in the fair value of contingent consideration related to CBIZ’s prior acquisitions.
(3)
Refer to the financial highlights tables for a reconciliation of Non-GAAP financial measures to the most directly comparable GAAP financial measure, and for additional information as to the usefulness of the Non-GAAP financial measures to shareholders and investors.
CBIZ, INC.
FINANCIAL HIGHLIGHTS (UNAUDITED)
(In thousands)
SELECT SEGMENT DATA
Three Months Ended June 30,
Six Months Ended June 30,
2024
2023
2024
2023
Revenue
Financial Services
$ 309,233
$ 290,930
$ 681,863
$ 634,016
Benefits and Insurance Services
97,419
95,838
205,827
195,892
National Practices
13,360
11,734
26,619
23,200
Total
$ 420,012
$ 398,502
$ 914,309
$ 853,108
Gross Margin
Financial Services
$ 46,424
$ 47,485
$ 153,493
$ 146,128
Benefits and Insurance Services
14,176
17,464
38,947
40,595
National Practices
1,332
1,189
2,658
2,072
Operating expenses – unallocated (1):
Other expense
(6,005)
(6,521)
(12,783)
(10,823)
Deferred compensation
(2,283)
(5,102)
(10,859)
(9,862)
Total
$ 53,644
$ 54,515
$ 171,456
$ 168,110
(1)
Represents operating expenses not directly allocated to individual businesses, including stock-based compensation, consolidation and integration charges, and certain advertising expenses. “Operating expenses – unallocated” also includes gains or losses attributable to the assets held in a rabbi trust associated with the Company’s deferred compensation plan. These gains or losses do not impact “Income before income tax expense” as they are directly offset by the same adjustment to “Other income (expense), net” in the Consolidated Statements of Comprehensive Income. Net gains or losses recognized from adjustments to the fair value of the assets held in the rabbi trust are recorded as compensation expense (income) in “Operating expenses” and “Corporate, general and administrative expenses,” and offset in “Other income (expense), net.”
CBIZ, INC.
SELECT CASH FLOW DATA (UNAUDITED)
(In thousands)
Six Months Ended June 30,
2024
2023
Net income
$ 96,677
$ 100,023
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense
19,008
17,831
Gain on sale of operations, net
—
(99)
Bad debt expense, net of recoveries
1,244
805
Adjustments to contingent earnout liability, net
638
1,445
Stock-based compensation expense
5,016
6,619
Other noncash adjustments
3,401
4,671
Net income, after adjustments to reconcile net income to net cash provided by operating activities
125,984
131,295
Changes in assets and liabilities, net of acquisitions and divestitures
(101,545)
(101,566)
Net cash provided by operating activities
24,439
29,729
Net cash used in investing activities
(33,247)
(65,617)
Net cash (used in) provided by financing activities
(11,920)
21,793
Net decrease in cash, cash equivalents and restricted cash
(20,728)
(14,095)
Cash, cash equivalents and restricted cash at beginning of year
$ 157,148
$ 160,145
Cash, cash equivalents and restricted cash at end of period
$ 136,420
$ 146,050
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:
Cash and cash equivalents
$ 1,128
$ 3,692
Restricted cash
44,947
52,314
Cash equivalents included in funds held for clients
90,345
90,044
Total cash, cash equivalents and restricted cash
$ 136,420
$ 146,050
CBIZ, INC.
SELECT FINANCIAL DATA AND RATIOS (UNAUDITED)
(In thousands)
June 30, 2024
December 31, 2023
Cash and cash equivalents
1,128
8,090
Restricted cash
44,947
30,362
Accounts receivable, net
477,841
380,152
Current assets before funds held for clients
562,808
453,499
Funds held for clients
131,128
159,186
Goodwill and other intangible assets, net
1,035,148
1,008,604
Total assets
2,160,805
2,043,592
Current liabilities before client fund obligations
336,140
352,028
Client fund obligations
131,623
159,893
Total long-term debt, net
379,660
310,826
Total liabilities
1,269,371
1,251,974
Treasury stock
(910,322)
(899,093)
Total stockholders’ equity
891,434
791,618
Debt to equity
42.6 %
39.3 %
Days sales outstanding (DSO) (1)
95
78
Shares outstanding
50,162
49,814
Basic weighted average common shares outstanding
50,079
49,989
Diluted weighted average common shares outstanding
50,248
50,557
(1)
DSO is provided for continuing operations and represents accounts receivable, net, at the end of the period, divided by trailing twelve months daily revenue. The Company has included DSO data because such data is commonly used as a performance measure by analysts and investors and as a measure of the Company’s ability to collect on receivables in a timely manner. DSO should not be regarded as an alternative or replacement to any measurement of performance under GAAP. DSO on June 30, 2023, was 94.
CBIZ, INC.
GAAP RECONCILIATION
Net Income and Diluted Earnings Per Share (“EPS”) to Adjusted Net Income, EPS and EBITDA(1)
(Unaudited. Amounts in thousands, except per share data)
Three Months Ended June 30,
2024
2023
Amounts
EPS
Amounts
EPS
Net income
$ 19,793
$ 0.39
$ 26,863
$ 0.53
Adjustments:
Integration & retention costs related to acquisitions (2)
330
0.01
865
0.03
Facility optimization costs (3)
85
—
221
—
Transaction costs (4)
6,651
0.13
—
—
Income tax effect related to adjustments
(1,906)
(0.03)
(330)
(0.01)
Adjusted net income
$ 24,953
$ 0.50
$ 27,619
$ 0.55
Interest expense
$ 5,884
$ 5,534
Income tax expense
8,400
11,746
Tax effect related to the adjustments above
1,906
330
Depreciation
3,520
3,116
Amortization
6,020
6,090
Adjusted EBITDA
$ 50,683
$ 54,435
Six Months Ended June 30,
2024
2023
Amounts
EPS
Amounts
EPS
Net income
$ 96,677
$ 1.92
$ 100,023
$ 1.98
Adjustments:
Transaction costs related to acquisitions (2)
—
—
611
0.01
Integration & retention costs related to acquisitions (2)
912
0.02
1,868
0.04
Facility optimization costs (3)
340
0.01
221
—
Transaction costs (4)
6,651
0.13
—
—
Income tax effect related to adjustments
(2,124)
(0.04)
(746)
(0.02)
Adjusted net income
$ 102,456
$ 2.04
$ 101,977
$ 2.01
Interest expense
$ 10,395
$ 9,175
Income tax expense
35,530
38,153
Gain on sale of operations, net
—
(99)
Tax effect related to the adjustments above
2,124
746
Depreciation
7,043
6,091
Amortization
11,965
11,740
Adjusted EBITDA
$ 169,513
$ 167,783
(1)
CBIZ reports its financial results in accordance with GAAP. This table reconciles Adjusted net income, Adjusted EPS, and Adjusted EBITDA to the most directly comparable GAAP financial measures, “Net income” and “Diluted earnings per share.” Adjusted net income, Adjusted EPS and Adjusted EBITDA are not defined by GAAP and should not be regarded as an alternative or replacement to any financial information determined under GAAP. Adjusted net income, Adjusted EPS and Adjusted EBITDA exclude significant non-operating related gains and losses that management does not consider on-going in nature. These Non-GAAP financial measures are used by the Company as performance measures to evaluate, assess and benchmark the Company’s operational results and to evaluate results relative to employee compensation targets. Accordingly, the Company believes the presentation of these Non-GAAP financial measures allows its stockholders, debt holders, and other interested parties to meaningfully compare the Company’s period-to-period operating results.
(2)
These costs include, but are not limited to, certain consulting, technology, personnel, as well as other first year operating and general administrative costs that are non-recurring in nature. Amounts reported in 2024 related to the costs incurred related to the acquisitions of Erickson, Brown & Kloster, LLC and CompuData, Inc., and those reported in 2023 related to the acquisition of Somerset CAPs and Advisors.
(3)
These costs relate to incremental non-recurring lease expense incurred as a result of CBIZ’s real estate optimization efforts.
(4)
These costs include, but are not limited to, certain non-recurring legal and other professional service costs incurred in connection with the announced purchase of Marcum.
CBIZ, INC.
GAAP RECONCILIATION
Full Year 2024 Diluted Earnings Per Share (“EPS”) Guidance to Full Year 2024 Adjusted Diluted EPS (1)
Full Year 2024 Guidance
Low
High
Diluted EPS – GAAP Guidance
$ 2.53
$ 2.58
Adjustments:
Integration & retention costs related to acquisitions (2)
0.01
0.01
Transaction costs (3)
0.10
0.10
Adjusted Diluted EPS Guidance
$ 2.64
$ 2.69
GAAP Diluted EPS for 2023
$ 2.39
$ 2.39
Adjusted Diluted EPS for 2023
$ 2.41
$ 2.41
GAAP Diluted EPS Range
6 %
8 %
Adjusted Diluted EPS Range
10 %
12 %
(1)
The full year 2024 guidance is based on management’s current expectations for the remainder of 2024, excluding the impact of the announced acquisition of Marcum. Management expects to update guidance for the combined business upon closing of the transaction, which is expected to occur in the fourth quarter, subject to the satisfaction of various closing conditions, including the approval of the Company’s stockholders.
(2)
These costs include, but are not limited to, certain non-recurring consulting, technology, personnel, and other first year operating and general administrative costs incurred related to the acquisitions of Erickson, Brown & Kloster, LLC and CompuData, Inc.
(3)
These costs include, but are not limited to, certain non-recurring legal and other professional service costs incurred in connection with the announced purchase of Marcum.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cbiz-reports-second-quarter-and-first-half-2024-results-and-announces-agreement-to-acquire-marcum-302210559.html
SOURCE CBIZ, Inc.
You may like
Technology
Tampax spotlights all-star athlete lineup led by Olivia Miles, bringing “Queen’s Court” fan experience to women’s basketball’s biggest moments
Published
13 minutes agoon
April 20, 2026By
CINCINNATI, April 20, 2026 /PRNewswire/ — Rising star Olivia Miles is leading Tampax’s growing roster of elite athletes, as the brand spotlights its commitment to supporting women in sport through confidence, performance and trusted protection.
Experience the full interactive Multichannel News Release here: https://www.multivu.com/tampax/9386052-en-tampax-and-all-star-lineup-brings-queens-court-fan-experience-to-wnba
All-star lineup empowering, educating women in sports
In partnership with WNBA draftee Olivia Miles and Olympic medalist Maia Shibutani, Tampax is continuing its commitment to support women in sport — bridging winter and summer athletes through a shared focus on performance and preparation.
“As an athlete, every detail matters when it comes to performance, and that includes how I manage my period,” said Miles. “Partnering with Tampax feels incredibly empowering because they truly understand the need for reliable protection that allows us to compete at the highest level without a second thought. But it’s more than just reliable protection; it’s about trusting the products you use on and off the court.”
“As an Olympic athlete, I know firsthand that periods don’t take a break for training or competition. The need for reliable, comfortable, and safe period care is universal across all sports – whether you’re on the ice, court, or anywhere else,” shared Shibutani. “Seeing organizations like Tampax step up to champion female athletes, and to provide products that instill confidence and trust, is vital for breaking down stigmas and empowering the next generation.”
As part of its associate partnership with the 2026 WNBA Draft presented by State Street Investment Management SPY, Tampax introduced “Queen’s Court,” an interactive, fan-facing experience designed to connect fans to the energy and culture of the game—bringing them closer to the athletes and moments shaping women’s basketball.
Tampax provided athletes and fans alike the opportunity to explore its unique space prior to the draft, which included access to #1 US OB/GYN recommended tampons *based on a 2026 survey designed for comfort and performance.
“Our partnership with the WNBA, and specifically our presence at the WNBA Draft with the Queen’s Court, is a natural and powerful alignment for Tampax,” said Chelsey Harshman, Senior Brand Director at Tampax.
“We understand the unique challenges women athletes face, and our mission is to ensure that period care is never a point of concern or limitation. By being the Official Period Protection Partner of the WNBA and the Toronto Tempo, we’re not just providing products; we’re providing confidence, comfort, and the assurance of trusted protection built on safe ingredients.”
Why is Tampax partnering with women’s professional sports?
Because performance doesn’t pause for a period.
Tampax is helping normalize conversations around periods and empowering women to be at their best while ensuring athletes have access to protection they can trust.
Through its women sports partnerships, Tampax is:
Providing reliable and safe period protection designed for athlete comfort and performanceHelping break stigma around periods in sportsReinforcing the importance of knowing and trusting the products athletes use
The goal is simple: give athletes one less thing to think about, so they can focus on their game.
About Olivia Miles
Olivia Miles is a rising star and one of the faces of the next generation of the WNBA. A native of Phillipsburg, New Jersey, she starred at Notre Dame before finishing her collegiate career at TCU. During her collegiate career, Miles earned All-American honors and multiple All-Conference selections, while consistently ranking among the national leaders in assists. She was selected as the No. 2 overall pick in the 2026 WNBA Draft, cementing her status as a rising star at the professional level.
About Maia Shibutani
Maia Shibutani is a two-time Olympic medalist, author, producer, and speaker. Alongside her brother and ice dance partner Alex Shibutani, she made history as part of the first ice dance team of Asian descent, and the first team of color, to medal at the Olympic Winter Games. The duo are three-time World medalists, five-time U.S. National Champions, and were inducted into the U.S. Figure Skating Hall of Fame in 2023.
Off the ice, Maia is a co-author of the “Kudo Kids” series and the children’s books Amazing: Asian Americans and Pacific Islanders Who Inspire Us All (2023) and Incredible: Asian Americans and Pacific Islanders Who Changed the World (2025), and is developing film and television projects. She is an advocate for education, diversity, and representation, serving in ambassador roles with organizations including the U.S. Department of State and Right To Play. Her honors include the Asia Society Game Changer Award, induction into the Asian Hall of Fame, and recognition as a Gold House A100 honoree.
About Tampax
Procter & Gamble‘s leading tampon brand, Tampax, exists to help women and girls better manage their periods through superior internal period protection and medically accurate period education. With more than 80 years of period protection expertise, Tampax meets a variety of needs with a product lineup that includes Tampax Pearl, Tampax Radiant, Tampax Pure Cotton, and Tampax Pocket Radiant. Only Tampax tampons offer a LeakGuard™ Braid and five absorbency sizes to help provide leak-free periods.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at https://www.pg.com/news.
Contact
Amanda Brown
Senior Communications Manager, North America Feminine Care
brown.a.8@pg.com
View original content:https://www.prnewswire.com/news-releases/tampax-spotlights-all-star-athlete-lineup-led-by-olivia-miles-bringing-queens-court-fan-experience-to-womens-basketballs-biggest-moments-302746382.html
SOURCE Tampax
Technology
Oracle Health Demonstrates Interoperability Leadership, Achieves CMS Aligned Network Status
Published
13 minutes agoon
April 20, 2026By
Delivers solution to eliminate check-in paperwork by leveraging CLEAR1 in support of CMS’ “Kill the Clipboard” initiative
AUSTIN, Texas, April 20, 2026 /PRNewswire/ — Advancing its mission to provide patients with access to their healthcare data when and where they need it, Oracle Health is now a Centers for Medicare & Medicaid Services (CMS) Aligned Network. Oracle Health has also developed and delivered an easy-to-implement solution that allows patients to digitally verify their identity and provide access to their health records at check-in. This eliminates redundant information gathering and reflects Oracle Health’s commitment to reducing the administrative burden across the healthcare ecosystem and increasing interoperability.
“Oracle Health is committed to making sure patients have access to and remain in control of their health data. Our participation in the CMS Aligned Networks will help health systems and patients connect data across settings, reduce fragmentation, and improve how clinicians and patients access the information they need,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “Oracle will continue working with government and industry leaders to deliver a secure, interoperable, and AI-enabled healthcare system that improves experiences for patients and clinicians while driving down the cost of care delivery.”
Streamlining the patient intake process
CMS’ “Kill the Clipboard” initiative encourages providers to replace paperwork intake processes with a seamless digital check in. Oracle will be integrating CLEAR1, CLEAR’s secure identity platform, to enable patients with a simple way to check in and give providers access to the health data they have opted to share by simply showing a QR code. The data will then flow directly into EHR workflows. CLEAR1 is Full Service certified by the Kantara Initiative for NIST Identity Assurance Level 2 (IAL2) and Authenticator Assurance Level 2 (AAL2), high-assurance standards that are foundational to trusted healthcare data exchange.
“Healthcare has long relied on fragmented, manual intake processes that create friction for patients and administrative burden for providers,” said David Bardan, SVP, Head of Healthcare, CLEAR. “By integrating CLEAR1 with Oracle Health, we’re working to help eliminate the clipboard entirely—enabling a simple, secure digital check-in that verifies the person and seamlessly connects their information into clinical workflows. This will be a meaningful step toward a more interoperable, patient-centered healthcare experience where trust, privacy, and ease of use are built into every interaction.”
New Jersey-based health system AtlantiCare is already using the solution to drive a better, more connected care experience for patients and providers.
“As one of the first healthcare systems in the nation to pledge support for the CMS Interoperability Framework, AtlantiCare is excited to partner with Oracle Health to deliver on that vision,” said Jordan Ruch, CIO of AtlantiCare. “We’ve completed full integration of this technology into our ambulatory check-in workflows, positioning us to deliver a faster, paper-free experience for patients, providers, and staff. This eliminates waiting room forms and repetitive medical history collection, with verified patient information flowing securely and seamlessly into our system as we prepare for broader rollout.”
Simplifying patient and provider access to health information
In addition to unveiling its offering to eliminate paperwork at check in, Oracle Health has taken another step toward helping accelerate secure, patient-centered healthcare data sharing by becoming a CMS Aligned Network. This most recent achievement builds on years of work enabling standards-based data exchange across care settings.
By becoming a CMS Aligned Network, Oracle Health has demonstrated its technology supports CMS-aligned approaches to simplify and accelerate healthcare data sharing for patients and providers. Oracle Health’s open and interoperable platform communicates with other CMS Aligned Networks as well as Qualified Health Information Networks® (QHINs) to create a single front door for patients to access and share their health information with providers.
Oracle Health is committed to enabling patient access to health data that is as simple as accessing bank records and is available conveniently when and where they need it. Last year, Oracle Health Information Network Inc., a subsidiary of Oracle, became a designated QHIN as a part of the Trusted Exchange Framework and Common Agreement™ (TEFCA™).
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-health-demonstrates-interoperability-leadership-achieves-cms-aligned-network-status-302746757.html
SOURCE Oracle
Technology
OrthAlign Accelerates Global Growth Strategy with Announcement of CE Mark in Europe
Published
14 minutes agoon
April 20, 2026By
IRVINE, Calif., April 20, 2026 /PRNewswire/ — OrthAlign, Inc., the leader in handheld orthopedic enabling technology, today announced it has received CE Mark under the EU MDR for its portfolio of navigation solutions, enabling commercialization across European markets. Both the Lantern® and OrthAlign Plus® platforms are now CE marked and available for sale.
This milestone expands access to OrthAlign’s proven technology across a region increasingly focused on efficiency, flexibility, and cost control in joint replacement.
OrthAlign’s handheld systems are well aligned with the needs of European healthcare systems. Delivered in a single-use format with per-case pricing, the technology eliminates the need for capital equipment, service contracts, and complex infrastructure. Hospitals and ambulatory surgical centers can more easily manage costs while maintaining access to advanced surgical technology.
“Our technology was designed to be accessible and easy to implement,” said Eric Timko, CEO of OrthAlign. “With no pre-operative imaging requirements, minimal training, and rapid product availability, we enable surgeons to adopt technology without disrupting existing workflows.”
OrthAlign’s open-platform supports compatibility with all major implant systems, giving surgeons flexibility across techniques and preferences while helping facilities standardize solutions across sites of care. It delivers consistent outcomes across total knee, revision knee, partial knee and total hip procedures.
With more than 450,000 procedures performed globally, OrthAlign has established a strong track record of delivering accurate, real-time data while maintaining procedural efficiency. The systems are designed to integrate seamlessly into the operating room, offering time-neutral performance compared to manual techniques without the added complexity of traditional navigation or robotics.
“The European market is increasingly prioritizing solutions that balance clinical performance with operational and economic efficiency,” added Timko. “We believe OrthAlign is uniquely positioned to meet that need.”
OrthAlign will begin immediate commercial rollout in key European markets, supported by distribution partners and clinical education programs. For distribution inquiries please contact info@orthalign.com.
About OrthAlign
OrthAlign, Inc. is a global medical device company focused on delivering simple, accurate, and cost-effective handheld technology for joint replacement surgery. Its product portfolio, including OrthAlign Plus and Lantern, empowers surgeons with real-time data to improve alignment and procedural efficiency, without the need for capital equipment.
View original content to download multimedia:https://www.prnewswire.com/news-releases/orthalign-accelerates-global-growth-strategy-with-announcement-of-ce-mark-in-europe-302747234.html
SOURCE OrthAlign
Tampax spotlights all-star athlete lineup led by Olivia Miles, bringing “Queen’s Court” fan experience to women’s basketball’s biggest moments
Oracle Health Demonstrates Interoperability Leadership, Achieves CMS Aligned Network Status
OrthAlign Accelerates Global Growth Strategy with Announcement of CE Mark in Europe
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Send Rakhi to UK swiftly with UK Gifts Portal
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Near Videos3 days agoWe Have Only Scratched The Surface Of The Agentic Future
-
Coin Market3 days agoSingapore Gulf Bank adds stablecoin mint and redeem for 24/7 settlement
-
Coin Market3 days agoFrench finance minister backs euro-pegged stablecoins to compete with US
-
Near Videos3 days agoNEAR Intern Demos the Future of Private Trading
-
Technology3 days agoDynamite Integrates Biometric Cryptography and AI into its Wallet Product
-
Coin Market2 days agoBitcoin mining difficulty falls, but projected to rise in next adjustment
-
Near Videos3 days agoAnthropic Cuts Off OpenClaw Subscribers | GPT-Image-2 Leaked | Drift $285M Hack Explained
-
Coin Market3 days agoUS Senator asks for Binance monitor update amid scrutiny of Iran sanctions
